Oral
Dato-DXd
AACR 2026 | April 17-22, 2026
Other/Multi
Antitumor activity of datopotamab deruxtecan in a co-clinical trial with patient derived xenografts
Dhruv Chachad
Poster
T-DXd
AACR 2026 | April 17-22, 2026
Breast Cancer
Comparison of digital and computational algorithms for quantifying human epidermal growth factor receptor 2 (HER2) protein expression in metastatic breast cancer (mBC) from clinical samples
Savitri Krishnamurthy
Poster
Pipeline Compounds
AACR 2026 | April 17-22, 2026
Other/Multi
DS-2243a, an HLA-A*02/NY-ESO–directed bispecific T-cell engager, shows potent anti-tumor activity in preclinical models of solid tumors
Junya Ichikawa
Poster
T-DXd
AACR 2026 | April 17-22, 2026
Gastric Cancer
First-line trastuzumab deruxtecan regimens in advanced HER2-positive gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: Exploratory analysis of baseline HER2-related biomarkers in DESTINY-Gastric03 part 2
Yelena Y. Janjigian
Poster
T-DXd
AACR 2026 | April 17-22, 2026
Gastric Cancer
First-line trastuzumab deruxtecan with rilvegostomig and fluoropyrimidine in HER2-positive gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: DESTINY-Gastric03 part 4 arm A results
Yelena Y. Janjigian
Poster
Dato-DXd
AACR 2026 | April 17-22, 2026
Lung Cancer
Immunomodulatory response in Dato-DXd-treated non-small cell lung cancer patient-derived organotypic tumor spheroids (pDOTS)
Satoru Yasuda
Poster
R-DXd
AACR 2026 | April 17-22, 2026
Gynecologic Cancers
Pharmacokinetic–tumor growth inhibition modeling of raludotatug deruxtecan (R-DXd) to support phase 3 dose selection in platinum-resistant ovarian cancer
YoungJun Yoo